Nancy H. Agee has maintained a consistent buying pattern across four companies since late 2023, with no recorded sales in her SEC Form 4 filings. Her transactions total $293,377.86 in purchases, concentrated primarily in Precigen Inc. (PGEN), Atlantic Union Bankshares (AUB), and RGC Resources (RGCO), with smaller positions in American National Bankshares (AMNB). The most significant activity occurred in PGEN, where Agee executed multiple purchases between August and September 2025 totaling $167,642.73, including a $69,000 acquisition on September 4, 2025. She continued accumulating PGEN shares as recently as March 2026 with a $56,496.96 purchase.
Agee’s investments in RGCO show a methodical approach, with nearly identical purchases of approximately $6,233 made monthly from July 2025 through January 2026. Her AUB activity includes a $19,987.92 acquisition in July 2025, though most other AUB transactions were non-monetary (likely awards or adjustments). The AMNB holdings, acquired in late 2023 and early 2024, were comparatively minor at roughly $2,800 each. With all recent transactions—including three buys in March 2026—being purchases, Agee’s filings reflect a clear accumulation strategy across small-cap financial and biotech stocks, particularly PGEN. The absence of sales suggests a long-term holding pattern.
AI-assisted summary